Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab Effect on Vascular Function in ASCVD
NCT03626831Phase 4Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Apr 2019
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in atherosclerotic cardiovascular disease (ASCVD) comparing Evolocumab with Placebo (2 arms). Primary endpoint: Percent change of Flow-Mediated Vasodilation at 8 weeks. Started Apr 2019; status: completed.
02
Drugs
evolocumab
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT03626831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03626831.